Body Vision Medical recently launched its lung cancer diagnostic platform the LungVision. The company will showcase its capabilities at the CHEST conference in San Antonio, Texas on October 7-10.

“This is an important day for us and for all those involved in the lung patient care worldwide,” said Body Vision CEO Dorian Averbuch. “Our technology is a major step toward winning the battle against lung cancer. We are targeting small pulmonary nodules that if diagnosed early, can be resected to cure the disease. Our clinical trials, in more than 400 patients with 12 leading lung cancer centers in the U.S., have demonstrated unmatched safety, accuracy and diagnostic yield. While seamlessly integrated into the standard bronchoscopy suite and workflow, our proprietary technology provides step-by-step guidance through planning, navigation, and lesion localization during biopsy, all with minimal learning curve.”

The platform has shown promise for using real-time imaging, artificial intelligence and intra-body navigation when detecting early-stage lung cancer.

“Body Vision provides a great tool that has changed the way we approached peripheral nodules. Its unique technology creates augmented reality with the ability to see fluoroscopically invisible lesions and the pathways under the live fluoro, while tracking a patient breathing,” Dr. Kyle Hogarth, director of bronchoscopy at the University of Chicago, said in a press release. “Once the technology has guided us to the lesion, we confirm the lesion’s relationship to the airway with radial-EBUS. We then use our off-the-shelf biopsy instruments via the LungVision catheter. The augmented fluoro image, integrated with the EBUS images, allows us to obtain tissue samples with continuous real-time confirmation of location. The beauty of it all is how simple and elegant the technology is.”